Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Federal Guidelines Recommend New HIV Testing Method

Published: Thursday, March 28, 2013
Last Updated: Thursday, March 28, 2013
Bookmark and Share
U.S. Department of Health and Human Services issues medical guidelines recommending genotypic testing to aid HIV therapy selection.

A new test based on gene sequencing may be used to assess a patient's suitability for treatment with CCR5 antagonists, a class of HIV antiretroviral therapies, under new medical guidelines issued by the U.S. Department of Health and Human Services (DHHS).

The new genotypic test performs comparably to the standard culture-based phenotypic tropism technique for predicting response to CCR5 antagonists, but at about half the cost and with faster results, according to Quest Diagnostics. Quest Diagnostics is believed to offer the only genotypic HIV tropism test service in the United States to demonstrate comparable performance to the standard phenotypic method, previously the only method available nationally to help physicians predict response to CCR5 antagonists.

"CCR5 antagonists can be an important component of an effective and well-tolerated drug combination in some HIV-infected patients. Tropism testing is a requirement for using this drug class, and fast test results facilitate timely treatment decisions," said Jonathan M. Schapiro, MD, director of HIV/AIDS at the National Hemophilia Center, Tel Hashomer, Israel. "The inclusion of genotypic tropism testing by the DHHS HIV Guidelines is a very welcome development. Faster, cost-effective diagnostics are greatly needed to improve HIV management."

Testing for HIV tropism is necessary to predict response to CCR5 antagonist therapy. This therapy can help slow HIV disease progression in patients with a certain type of tropism, but offer no known clinical benefit in patients with other forms of tropism. Tropism refers to a type of cellular mechanism by which the HIV virus infects human cells.

The revised DHHS guidelines, titled Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, recommend "that a genotypic tropism assay be used as an alternative to a phenotypic tropism assay before initiation of a CCR5 antagonist-containing regimen." While prior HHS guidelines only recommended phenotypic assays, medical guidelines in Europe have supported genotypic HIV tropism tests since 2011.

The DHHS guidelines are available at: http://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/0/

"Genotyping is an example of how diagnostic innovation can expand clinical options for physicians while driving down costs for payers and patients," said Rick L. Pesano, M.D., Ph.D., medical director, infectious diseases, Quest Diagnostics. "We expect this method will provide the basis for developing additional diagnostic innovations that are clinically valuable and more cost effective than traditional techniques."

Quest Diagnostics has offered its clinical genotypic tropism test as a laboratory-developed test, named the Quest Diagnostics HIV-1 Tropism with Reflex to Ultradeep sequencing (UDS), since the spring of 2012. The company's advanced genetics laboratory in San Juan Capistrano, California, developed, validated and performs the test for clinicians in the United States. Quest Diagnostics can provide test results in as few as 10 business days, compared to average turnaround times of two to three weeks for phenotypic tests, and at roughly half the list price for the standard phenotypic test.

In late 2012, the peer-reviewed, open-access journal PLOS ONE published a study that found the Quest Diagnostics deep-sequencing genotypic method predicted response to HIV antiretroviral therapy as well as the industry's standard phenotypic test.

Quest Diagnostics has one of the most comprehensive HIV testing services menu in the diagnostic industry, with services that range from HIV screening, viral load, therapeutic monitoring, co-infection and resistance testing. In late 2012, the company launched the HIV proviral DNA tropism lab-developed test, which uses DNA extraction and sequencing followed by bioinformatic analysis to help enable genotypic tropism testing for patients with low or undetectable HIV-1 viral RNA.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

HIV Genotypic Sequencing Test Comparable to Standard Phenotypic Test in Predicting Antiretroviral Response
Genotypic HIV tropism laboratory-developed testing service now available nationally for HIV-infected patients.
Wednesday, October 03, 2012
Quest Diagnostics Launches First Molecular Test for Kidney Organ Transplant Rejection
The Renal Transplant Monitoring laboratory-developed test is designed to help physicians detect kidney failure weeks before conventional tests or clinical symptoms signify damage.
Monday, March 19, 2012
New York State Approves Quest Diagnostics' Fragile X Syndrome Test
XSense® is said to be the first laboratory test that may be suitable for population-based screening for Fragile X Syndrome.
Friday, July 30, 2010
Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland
Quest to provide screening services intended to improve medical outcomes for women who participate in Ireland's first nationwide cytology-screening program.
Monday, June 23, 2008
Quest Diagnostics Licenses Technology Underlying SensiTrop™ HIV Co-Receptor Tropism Test from Pathway Diagnostics
Quest Diagnostics licenses the heteroduplex tracking technology underlying Pathway's SensiTrop™ HIV co-receptor tropism test.
Tuesday, October 30, 2007
Quest Introduces ClariSure™ Test for Identifying Chromosome Abnormalities in Children
The molecular diagnostic test is designed to detect chromosome abnormalities associated with 85 developmental disorders affecting children.
Monday, September 03, 2007
Quest Diagnostics Launches Test to Predict Risk of Breast Cancer Recurrence in Women
Quest Diagnostics has introduced a test which can help physicians to predict the risk of disease recurrence in women with ER-positive, lymph node-negative breast cancer.
Tuesday, December 19, 2006
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Cell Aging Slowed by Putting Brakes on Noisy Transcription
Experiments in yeast hint at ways to extend life of some human cells.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
The Genetic Roots of Adolescent Scoliosis
Scientists at the RIKEN Center for Integrative Medical Sciences in collaboration with Keio University in Japan have discovered a gene that is linked to susceptibility of Scoliosis.
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
How a Kernel Got Naked and Corn Became King
Ten thousand years ago, a golden grain got naked, brought people together and grew to become one of the top agricultural commodities on the planet.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!